AOD 9604 Peptide: The hGH Fragment for Fat Loss and Tissue Repair

At a Glance

Among the peptides that have made their way from academic endocrinology into integrative clinical practice, AOD 9604 occupies a distinctive niche. It is not a weight-loss drug in the conventional sense. It is a precisely engineered fragment of human growth hormone, designed to reproduce one specific physiological action — fat mobilisation — while shedding the properties of full-length hGH that make it problematic: IGF-1 elevation, insulin resistance, and anabolic signalling. For physicians who work with patients carrying complex metabolic profiles, that trade-off is clinically meaningful.

Patients ask me about AOD 9604 mainly in two contexts: weight that resists diet and exercise, and fatigue and weight gain after an infection such as Lyme disease or COVID. The honest answer is more sobering than the marketing. The engineering idea was elegant, the safety data from the developer’s trials were reassuring, and the weight-loss effect in people was too small to make it a medicine. This page explains the evidence, the regulatory status and the doses used in practice.

What AOD 9604 Is — and What It Is Not

The hGH Molecule and the Fat-Loss Fragment

Human growth hormone (hGH) is a 191-amino-acid protein with a pleomorphic biological profile. Its anabolic effects — muscle and bone growth — are mediated primarily through IGF-1 induction after binding to the GH receptor. Its lipolytic effects, however, appear to be mediated through a separate mechanism located in the C-terminal domain of the protein.

AOD 9604 isolates residues 177–191 of the hGH sequence and adds a tyrosine residue at the N-terminus (hence “Tyr-hGH177-191”), a modification that improves stability without altering biological activity. This fragment does not bind the classical GH receptor and does not induce IGF-1. This was confirmed in early in vitro studies by researchers at Monash University who were mapping the functional domains of hGH for what eventually became a drug development programme at Metabolic Pharmaceuticals.

The consequence is that AOD 9604 can stimulate fat metabolism through a pathway that is essentially orthogonal to the growth-promoting and glucose-altering pathways of full-length growth hormone.

Mechanism: How It Burns Fat

The fat-metabolising activity of AOD 9604 operates via two complementary pathways:

1. Lipolysis stimulation. AOD 9604 activates β3-adrenergic receptors on adipocytes. β3-AR stimulation triggers adenylyl cyclase, raises intracellular cAMP, activates protein kinase A, and phosphorylates hormone-sensitive lipase (HSL) — the enzyme that hydrolyses stored triglycerides into free fatty acids and glycerol. The result is fat mobilisation from adipose stores.

2. Lipogenesis inhibition. Simultaneously, AOD 9604 suppresses the activity of fatty acid synthase (FAS) and reduces the conversion of dietary carbohydrate into fat. This dual action — releasing stored fat while reducing new fat synthesis — is the mechanistic basis for its anti-obesity effect.

Animal studies conducted at Metabolic Pharmaceuticals demonstrated that obese mice treated with AOD 9604 lost weight specifically through fat mass reduction, with lean mass spared, and that the peptide had no effect on bone growth or blood glucose — distinguishing it cleanly from full-length hGH.

Clinical Evidence: What the Trials Show

AOD 9604 has a more substantial human trial record than most peptides sold today. Metabolic Pharmaceuticals ran six randomised, double-blind, placebo-controlled trials from the late 1990s to the mid-2000s. The pooled safety data were later published (Stier 2013): tolerability was indistinguishable from placebo, IGF-1 and glucose tolerance were unchanged, and no anti-AOD9604 antibodies were found in the patients tested. The largest trial ran for 24 weeks; the doses studied were 0.25, 0.5 or 1 mg daily as oral tablets against placebo.

What the Efficacy Data Show

The efficacy results were reported mainly by the developer and were never published in full in a peer-reviewed journal. Earlier, smaller studies reported modest weight loss. The larger, later trial did not show clinically meaningful weight loss compared with placebo, and development of AOD 9604 as an obesity drug was stopped. That outcome is the most important fact on this page: the one serious attempt to prove it works for fat loss in people did not succeed.

What That Means in Practice

AOD 9604 is not an approved medicine for obesity or anything else in the US, the EU or Germany. Compared with the approved GLP-1 medicines, whose effect sizes are well documented in large trials, it has no demonstrated clinical benefit. Claims that it works “as part of a protocol” have not been tested.

Dosing and Administration

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Standard Dosing Protocol

The developer’s trials gave AOD 9604 by mouth (0.25–30 mg once daily in the phase IIb trials, up to 54 mg daily in a 7-day safety study) or as single intravenous doses. No trial tested subcutaneous injection, so the injected doses below come from practice protocols (see the table further down), not from the trials:

• Starting dose: 200–300 mcg subcutaneous injection once daily
• Maintenance dose: 300–500 mcg once daily
• Timing: Morning injection, fasted or 30 minutes before exercise — this aligns the peak lipolytic effect with periods of low insulin when free fatty acid oxidation is most efficient
• Cycle length: 8–16 weeks (Practice protocol). The break between courses, often 4–8 weeks, is convention; no data show it is needed or that it helps
• Upper range: 400–500 mcg once daily, or 250 mcg twice daily, in higher-dose practice protocols (Practice protocol). The 1 mg/day top dose of the 24-week trial was oral, so it says nothing about the safety of 1 mg injected

Subcutaneous Injection Technique

Rotate injection sites among the abdomen (preferred), outer thigh, and lateral hip. Many practitioners and patients favour periumbilical injection sites based on the theoretical advantage of regional depot fat delivery, though the pharmacokinetic evidence for local lipolytic enhancement at injection sites is not conclusive for peptides of this size.

AOD 9604 is supplied as a lyophilised powder reconstituted with bacteriostatic water. Standard reconstitution: 2 mg vial into 2 mL bacteriostatic water yields a 1 mg/mL (1,000 mcg/mL) solution. A 300 mcg dose requires 0.3 mL.

Oral Formulations

Oral versions are available through compounding pharmacies, but bioavailability is substantially lower and more variable than subcutaneous injection, and it has not been quantified in published human data. Oral AOD 9604 may suit patients unwilling to inject who accept a reduced effect ceiling.

Product Quality and Regulatory Status

AOD 9604 sold online is usually labelled “research use only”, which means it has not been made or tested for human use, and the buyer cannot check content, purity or sterility. FDA lists AOD-9604 among bulk substances that may present significant safety risks in compounding, citing concerns such as immunogenicity and peptide impurities. It is not on the 503A bulks list and not in category 1. The practical risks of self-injecting research peptides are covered in How to Inject Peptides: A Step-by-Step Patient Guide and Peptide Sourcing: Pharmaceutical-Grade vs. Grey Market.

(Note: “Adipotide” is an unrelated experimental compound, a pro-apoptotic peptide targeting fat-tissue blood vessels, and not an oral form of AOD 9604.)

Protocol table

No trial ever tested the injected dose. All six developer trials gave AOD 9604 either as a single intravenous dose or by mouth as capsules or tablets, at 0.25 to 54 mg per day. The subcutaneous 250-500 mcg used in practice was never studied for effect or safety, so the trial safety record describes oral and intravenous exposure, not daily injections. Headache was the most common adverse event in those trials (16 of 23 men across the drug and placebo periods of one intravenous study), and the authors judged overall tolerability indistinguishable from placebo.

Oral microgram doses. The trials needed milligram doses by mouth; the 300-600 mcg oral protocols in circulation are one to two orders of magnitude lower, and nobody has measured whether they are absorbed at all.

What people report: what works and what doesn’t

Sources: the aggregated community data sets (Peptide Protocol Wiki, 90 reports; Peptide DB), the off-label dosing patterns in a peer-reviewed review (Dominikowski 2026), and the developer’s published safety summary (Stier 2013). Patterns, not proof.

Reported to work

• Modest, gradual fat loss at 300 mcg daily, usually first noticed at 8-12 weeks and often described by users themselves as subtle.
• No change in appetite and no effect on blood sugar. This matches the trials, which found no effect on glucose tolerance or IGF-1.
• Good tolerability. Few side effects are reported, in line with the trial summary.

Mixed or unclear

• Whether anything happened at all. A substantial share of users describe the effect as underwhelming, and self-reported fat loss is hard to separate from the diet and training changes that usually start at the same time.
• Joints and cartilage. Sometimes used at 250 mcg daily for joint support. The basis is one rabbit study of weekly injections of 0.25 mg directly into the knee (Kwon 2015); there are no human joint data, and daily injections under the skin are a different exposure.
• Twice-daily splitting (250 mcg morning and evening). Popular, with no data showing it does more than a single dose.

Reported not to work, or disappointing

• Clinically meaningful weight loss. The largest phase IIb trial, at oral doses, did not deliver it, and the community data set notes that expectations online run well ahead of the trial results.
• Oral microgram protocols. No evidence they are absorbed; the trials used milligram doses by mouth.
• Side effects described: mild injection-site reactions in the reference sources, and in the trials mainly headache, followed by digestive complaints such as diarrhoea, flatulence and nausea. FDA notes serious adverse events that may be associated with AOD-9604, though causality is not clear, which is one reason it sits on FDA’s list of compounding substances with safety concerns.

What a properly designed trial would need to show: a randomised, placebo-controlled trial of at least 24 weeks of the subcutaneous 250-500 mcg doses actually used, in adults with overweight or obesity on a standardised diet, with DEXA fat and lean mass, waist circumference, glucose and lipid markers, and injection-site and antibody monitoring.

AOD 9604 in Post-Infectious Metabolic Dysfunction

This is the use I am asked about most after obesity, so it deserves a careful look at what is mechanism and what is speculation.

Patients recovering from chronic Lyme disease, reactivated viral infections (EBV, HHV-6), or post-COVID syndrome frequently present with adipose-centric metabolic dysfunction that is qualitatively different from simple dietary obesity. Adipose tissue acts as a reservoir for lipopolysaccharide (LPS), lipophilic biotoxins (including those produced by mold and borrelia), and inflammatory mediators including IL-6, TNF-α, and adiponectin dysregulation. Adipose-resident macrophages in states of chronic immune activation sustain low-grade inflammation that both perpetuates symptoms and resists standard dietary interventions.

The idea that faster lipolysis would “mobilise” stored toxins and inflammatory load, and that this would help post-infectious symptoms, is a hypothesis. No study has tested AOD 9604 in post-Lyme, post-COVID or similar patients, and no study has shown that it changes symptoms, inflammatory markers or toxin levels in anyone. If anything, rapid release of stored lipophilic compounds is a theoretical reason for caution, not a benefit.

For post-infectious fatigue and weight change, the useful steps are the unglamorous ones: a careful work-up for treatable causes (thyroid, iron, sleep apnoea, depression, medication effects, persistent infection), structured activity pacing, and nutrition. Combinations of AOD 9604 with other unapproved peptides such as BPC-157 have never been studied; see Peptide Stacking: A Physician’s Guide to Combining BPC-157, TB-500, and GHK-Cu.

Combining AOD 9604 with Other Metabolic Agents

AOD 9604 + CJC-1295/Ipamorelin

This is the most common combination in peptide therapy practice. CJC-1295 and Ipamorelin stimulate endogenous GH release via GHRH and ghrelin receptor pathways respectively. The pulsatile GH release they induce provides anabolic, recovery, and sleep-quality benefits. AOD 9604 adds direct lipolytic action without further stimulating IGF-1. The combination targets complementary aspects of metabolic optimisation: body recomposition (GH secretagogues driving lean mass, AOD 9604 driving fat mass reduction). For a full review of CJC-1295/Ipamorelin dosing, see our CJC-1295 Ipamorelin guide. Note that CJC-1295 and ipamorelin carry their own FDA safety flags (serious adverse events including raised heart rate and, for intravenous ipamorelin, a death).

AOD 9604 + Semaglutide or Tirzepatide

GLP-1 receptor agonists and AOD 9604 have additive rather than synergistic mechanisms. GLP-1 agonists reduce caloric intake through appetite suppression and gut motility effects; AOD 9604 enhances fat mobilisation independent of caloric restriction. When AOD 9604 is added during a GLP-1 programme — particularly with pronounced visceral adiposity — the dose used is typically 300 mcg/day. No pharmacokinetic interactions are known, although none have been formally studied. Dosing of semaglutide and tirzepatide follows the official prescribing information, so discuss any additional product with the prescriber.

AOD 9604 + Berberine

Berberine activates AMPK and improves insulin sensitivity; AOD 9604 works upstream via the β3-AR pathway. Both promote fat oxidation through different mechanisms and neither significantly affects the other’s pharmacological action. This combination is used in metabolic syndrome where insulin resistance and excess adiposity co-exist.

None of these combinations has been tested in a controlled human trial.

Safety Profile and Contraindications

What the Evidence Says

In the developer’s trials, which used pharmaceutical-grade material under trial conditions, AOD 9604’s safety profile was reassuring. Key findings from the published safety summary:

• No IGF-1 rise: unlike full-length hGH, IGF-1 was not elevated, which lowers (but does not remove) the theoretical concern about proliferative effects; long-term cancer data do not exist
• No glucose metabolism disruption in the trial populations
• No suppression of endogenous GH axis: it does not participate in the GHRH/somatostatin feedback loop
• Cardiovascular parameters: blood pressure, heart rate, and ECG findings were unchanged in trial populations
• No hepatotoxicity: liver enzymes unaffected across all Phase 2 studies

Reported Adverse Effects

• Injection site reactions with injected product: redness, induration, bruising
• Transient nausea
• Mild headache
• With grey-market product: risks from wrong content, impurities, contamination and immune reactions, none of which the trial data cover

Contraindications and Cautions

• Active malignancy: general peptide caution; insufficient data to recommend
• Pregnancy and breastfeeding: contraindicated; category not established
• Severe renal or hepatic impairment: exercise caution; no specific trial data
• Competitive athletes: WADA prohibits AOD-9604 (S2.2.3, growth hormone fragments)

Regulatory Status

AOD 9604 is not approved as a medicine by the FDA, the EMA or Germany’s BfArM. FDA lists it among bulk drug substances for compounding that may present significant safety risks (nominations withdrawn; page current as of April 2026), and it is not in 503A category 1. Selling a vial as “research use only” avoids drug approval; it says nothing about whether the contents are safe or tested in people.

Related Articles

• Peptide Stacking: A Physician’s Guide to Combining BPC-157, TB-500, and GHK-Cu
• CJC-1295 / Ipamorelin: Growth Hormone Peptide Protocol
• BPC-157: Mechanisms, Dosing, and Clinical Applications
• Berberine for Blood Sugar and Metabolic Health
• Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?
• HGH Fragment 176-191: The Unmodified Fragment vs AOD-9604
• Adipotide (FTPP): Fat-Cell Ablation and the Kidney Problem